Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIDaC trial of de-escalated first-line immunotherapy strategy in metastatic NSCLC
NL-OMON59552Phase 3Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Leiden University Medical Center. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59552.